Since IL-1β signaling plays a key role in AML progression, multiple IL-1 blockers, including the FDA-approved canakinumab, anakinra, and rilonacept [14,15], might be beneficial in treating patients displaying preleukemic conditions, such as IBMFSs. Here, IL1B is linked to acute myeloid leukemia.